Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021091310 - NOVEL HUMAN EPIDERMAL GROWTH FACTOR FUSION PROTEIN AND USE THEREOF

Publication Number WO/2021/091310
Publication Date 14.05.2021
International Application No. PCT/KR2020/015517
International Filing Date 06.11.2020
IPC
C07K 14/485 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
485Epidermal growth factor (EGF) (urogastrone)
A61K 8/64 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
64Proteins; Peptides; Derivatives or degradation products thereof
A61K 38/18 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
A61P 17/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61Q 19/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
19Preparations for care of the skin
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Applicants
  • 한국해양과학기술원 KOREA INSTITUTE OF OCEAN SCIENCE & TECHNOLOGY [KR]/[KR]
Inventors
  • 오철홍 OH, Chul Hong
  • 강도형 KANG, Do Hyung
  • 이영득 LEE, Young Deuk
  • 장덕희 JANG, Duck Hee
  • 조은영 JO, Eun Young
  • 히테아라치사지트라 아마린 HETTIARACHCHI, Sachithra Amarin
  • 강윤혁 KANG, Yoon Hyeok
  • 엄태양 EOM, Tae Yang
  • 강예희 GANG, Ye Hui
Agents
  • 김순웅 KIM, Soon Woong
Priority Data
10-2019-014249708.11.2019KR
10-2020-014711405.11.2020KR
Publication Language Korean (KO)
Filing Language Korean (KO)
Designated States
Title
(EN) NOVEL HUMAN EPIDERMAL GROWTH FACTOR FUSION PROTEIN AND USE THEREOF
(FR) NOUVELLE PROTÉINE DE FUSION DU FACTEUR DE CROISSANCE ÉPIDERMIQUE HUMAIN ET SON UTILISATION
(KO) 신규한 인간 상피세포성장인자 융합 단백질 및 이의 용도
Abstract
(EN)
The present invention relates to a novel human epidermal growth factor (hEGF) fusion protein and a use thereof. More specifically, the hEGF fusion protein of the present invention comprises: a Bacillus subtilis CH2-derived chitosanase signal peptide; hEGF; and polyarginine which is a cell-penetrating peptide. When the hEGF fusion protein is used, the water solubility and expression of a target protein increase, and useful effects, such as increased skin cell growth and a wound healing effect, are notably enhanced, and thus the hEGF fusion protein may be widely used in various industries as an active ingredient of a functional cosmetic composition and pharmaceutical composition.
(FR)
La présente invention concerne une nouvelle protéine de fusion du facteur de croissance épidermique humain (hEGF) et son utilisation. Plus particulièrement, la protéine de fusion hEGF selon la présente invention comprend : un peptide signal de chitosanase dérivé de Bacillus subtilis CH2; hEGF; et une polyarginine qui est un peptide de pénétration cellulaire. L'utilisation de la protéine de fusion hEGF selon l'invention permet d'améliorer de manière remarquable la solubilité dans l'eau et l'expression d'une augmentation de protéine cible, ainsi que des effets utiles, tels qu'une augmentation de la croissance des cellules de la peau et un effet de cicatrisation des plaies, et par conséquent, la protéine de fusion hEGF peut être largement utilisée dans diverses industries en tant que principe actif d'une composition cosmétique fonctionnelle et d'une composition pharmaceutique.
(KO)
본 발명은 본 발명은 신규한 인간 상피세포성장인자 융합 단백질 및 이의 용도에 관한 것으로, 보다 구체적으로, 본 발명의 인간 상피세포성장인자(hEGF) 융합 단백질은, 바실러스 서브틸리스 CH2-유래 키토산아제 시그널 펩타이드; 인간 상피세포성장인자(hEGF); 및 세포투과 펩타이드인 폴리아르기닌로 구성되어 있으며, 이를 이용할 경우, 목적 단백질의 수용성 및 발현율이 향상될 뿐만 아니라, 피부 세포 성장 증가 및 상처 치유 효과와 같은 유용한 효능이 현저하게 증진하였는바, 기능성 화장료 조성물 및 약학 조성물의 유효성분으로서 다양한 산업에 널리 활용될 수 있다.
Latest bibliographic data on file with the International Bureau